![]() |
市場調查報告書
商品編碼
1930155
止鼾器市場規模、佔有率、成長及全球產業分析:按類型、應用和地區劃分的洞察,2026-2034 年Anti-snoring Devices Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034 |
||||||
全球止鼾器市場正經歷顯著成長,這主要得益於睡眠障礙盛行率的上升以及人們對打鼾健康影響的認識不斷提高。預計到 2025 年,該市場規模將達到 11.5 億美元,到 2026 年將成長至 11.4 億美元,到 2032 年將達到 20 億美元,預測期內複合年增長率 (CAGR) 為 7.40%。北美地區在 2025 年將佔市場主導地位,市場佔有率達 37.88%,這主要歸因於阻塞性睡眠呼吸中止症 (OSA) 的高盛行率以及慢性打鼾人群的龐大。
止鼾器是一種非侵入性解決方案,旨在透過在睡眠期間打開呼吸道來減少或預防打鼾。這些裝置包括下顎前移裝置 (MAD)、舌頭固定裝置 (TRD)、頦帶和鼻擴張器,可有效治療輕度至中度阻塞性睡眠呼吸中止症 (OSA)。非處方止鼾器日益普及,進一步推動了全球市場成長。
市場由瑞思邁 (ResMed)、費雪派克醫療保健有限公司 (Fisher & Paykel Healthcare Limited) 和 SomnoMed 等主要公司主導,這些公司擁有強大的全球影響力和多元化的產品組合。
市場動態
市場驅動因素
睡眠障礙(例如打鼾和阻塞性睡眠呼吸中止症 (OSA))的盛行率不斷上升,是止鼾器市場的主要驅動因素。據估計,全球約有9.36億30至69歲的成年人患有輕度至重度阻塞性睡眠呼吸中止症(OSA),這推動了對無創、經濟實惠且舒適的治療方案的需求。止鼾設備為侵入且昂貴的正壓通氣療法和手術幹預提供了一種有效的替代方案。提高舒適度、療效和患者依從性的技術創新正在推動止鼾設備的進一步普及。
市場限制因子
儘管市場成長,但由於消費者認知度和接受度較低,市場仍面臨挑戰。許多人並不了解打鼾是一種需要介入的疾病。對止鼾設備不適感和療效不足的誤解也限制了其接受度。此外,發展中國家診斷設施的缺乏和相關知識的匱乏也阻礙了市場滲透。例如,截至2023年,美國40.3%被診斷出患有睡眠呼吸中止症的成年人未嘗試過任何治療。
市場機會
新興市場為止鼾設備製造商提供了巨大的機會。可支配收入的成長、醫療意識的提高以及診斷設施的改善正在推動亞太地區、拉丁美洲和非洲部分地區等地的需求。各公司正利用本地宣傳活動、與醫療服務提供者的策略合作以及價格親民的產品線來擴大市場覆蓋範圍並促進產品普及。
市場挑戰
與正壓通氣(PAP)設備以及懸雍垂腭咽成形術(UPPP)和射頻消融術等外科手術的競爭構成了一項挑戰。 PAP設備由醫療專業人員開立處方,並且通常包含在保險範圍內,因此是中重度阻塞性睡眠呼吸中止症(OSA)患者的首選治療方案。外科手術可以提供長期緩解,並減少對非處方設備的依賴。 2019年,美國進行了約18,526例OSA手術,反映出人們對臨床治療的強烈偏好。
市場趨勢
非侵入式、技術驅動的解決方案是關鍵的市場趨勢。整合感測器、人工智慧和藍牙連接的智慧型裝置可實現個人化治療方案、即時監測和行動應用程式整合。例如,ProSomnus 的 EVO[PH] 裝置於 2022 年獲得 FDA 批准,它透過在睡眠期間調整下顎位置來提高舒適度和依從性。與遠距醫療診斷和可穿戴技術的整合正在擴大市場並吸引註重健康的消費者。
依裝置類型
依通路劃分
北美:2025年市場規模達4億美元,預計2026年將達4.3億美元,引領市場。光是美國一地,由於打鼾的高發生率和治療率,預計到2026年市場規模將達到4.1億美元。
歐洲:在成熟的供應鏈和主要參與者的支持下,預計將以7.4%的複合年增長率增長,到2026年達到3.2億美元。英國、德國和法國是主要貢獻者。
亞太地區:預計2026年將達到2.8億美元,其中印度和中國分別貢獻4,000萬美元和1.1億美元。成長主要受意識提升和醫療基礎設施改善的推動。
拉丁美洲:預計到 2026 年將達到 7,000 萬美元,主要受 OSA 患者意識提升的推動。
中東和非洲:預計到 2025 年,海灣合作委員會 (GCC) 地區的市場規模將達到 2,000 萬美元。
The global anti-snoring devices market is witnessing significant growth, driven by the rising prevalence of sleep disorders and increasing awareness about the health impacts of snoring. The market was valued at USD 1.15 billion in 2025 and is projected to grow to USD 1.14 billion in 2026, reaching USD 2 billion by 2032, reflecting a CAGR of 7.40% over the forecast period. North America dominated the market in 2025 with a 37.88% share, primarily due to high prevalence of obstructive sleep apnea (OSA) and a large population of regular snorers.
Anti-snoring devices are non-invasive solutions that help reduce or prevent snoring by keeping the airway open during sleep. These devices include mandibular advancement devices (MADs), tongue retaining devices (TRDs), chin straps, and nasal dilators, which are also effective in managing mild to moderate OSA. The increasing penetration of over-the-counter anti-snoring devices is further supporting market growth globally.
The market is led by major players such as ResMed, Fisher & Paykel Healthcare Limited, and SomnoMed, who hold a strong global presence and a diversified product portfolio.
Market Dynamics
Market Drivers
The rising prevalence of sleep disorders such as snoring and obstructive sleep apnea is a key driver for anti-snoring devices. Globally, an estimated 936 million adults aged 30-69 have mild to severe OSA, increasing the demand for non-invasive, affordable, and comfortable treatment solutions. Anti-snoring devices offer an effective alternative to airway pressure therapy and surgical interventions, which are often invasive and expensive. Technological innovations that improve comfort, efficacy, and patient compliance further drive adoption.
Market Restraints
Despite growth, the market faces challenges due to limited consumer awareness and adoption. Many individuals are unaware that snoring is a medical condition requiring intervention. Misconceptions regarding discomfort or inefficacy also restrict acceptance. Additionally, the lack of diagnostic facilities and limited knowledge in developing countries hinder market penetration. For example, 40.3% of U.S. adults diagnosed with sleep apnea had not tried any treatment as of 2023.
Market Opportunities
Emerging markets present significant opportunities for anti-snoring device manufacturers. Rising disposable incomes, improved healthcare awareness, and better diagnostic facilities in regions such as Asia Pacific, Latin America, and parts of Africa are fueling demand. Companies are leveraging localized awareness campaigns, strategic partnerships with healthcare providers, and affordable product lines to expand market reach and increase adoption.
Market Challenges
Competition from positive airway pressure (PAP) therapy devices and surgical interventions such as Uvulopalatopharyngoplasty (UPPP) or radiofrequency ablation poses challenges. PAP devices are often prescribed by healthcare professionals and covered by insurance, making them a preferred choice for moderate to severe OSA patients. Surgical interventions offer long-term relief, reducing reliance on over-the-counter devices. In the U.S., there were around 18,526 surgical encounters for OSA in 2019, reflecting strong preference for clinical treatments.
Market Trends
Non-invasive and tech-driven solutions are key market trends. Smart devices incorporating sensors, AI, and Bluetooth connectivity enable personalized treatment plans, real-time monitoring, and integration with mobile apps. Devices like ProSomnus' EVO [PH], FDA-cleared in 2022, offer jaw adjustment during sleep, enhancing comfort and compliance. Remote diagnosis through telemedicine and wearable technology integration are expanding the market and attracting health-conscious consumers.
By Device Type:
By Distribution Channel:
North America: Dominated the market in 2025 with USD 0.4 billion, projected to reach USD 0.43 billion in 2026. The U.S. alone is estimated to account for USD 0.41 billion in 2026 due to high snoring prevalence and treatment rates.
Europe: Projected to grow at a 7.4% CAGR, reaching USD 0.32 billion in 2026, supported by established supply chains and key players. The U.K., Germany, and France are major contributors.
Asia Pacific: Estimated at USD 0.28 billion in 2026, with India and China contributing USD 0.04 billion and 0.11 billion, respectively. Growth is driven by rising awareness and improving healthcare infrastructure.
Latin America: Expected to reach USD 0.07 billion in 2026, with increased awareness among OSA patients.
Middle East & Africa: GCC countries expected to reach USD 0.02 billion in 2025.
Competitive Landscape
Major players include SomnoMed (Australia), ResMed (U.S.), Glidewell (U.S.), Panthera Dental (Canada), Fisher & Paykel Healthcare (New Zealand), ProSomnus Sleep Technologies (U.S.), and others. Companies focus on product innovation, geographic expansion, and awareness campaigns. Strategic collaborations, like Rotech Healthcare and Signifier Medical partnership in 2024, strengthen distribution and product accessibility.
Conclusion
The global anti-snoring devices market is projected to grow from USD 1.15 billion in 2025 to USD 2 billion by 2032, at a CAGR of 7.40%. Growth is fueled by the rising prevalence of sleep disorders, technological innovations in smart and non-invasive devices, and expanding awareness in emerging markets. While challenges remain from limited consumer adoption and competition from PAP therapy and surgical solutions, market opportunities in developing regions and technological advancements position the anti-snoring devices market for sustained growth through 2032.
Segmentation By Device Type, Distribution Channel, and Region
By Device Type * Mandibular Advancement Devices
By Distribution Channel * Hospital Pharmacies
By Geography * North America (By Device Type, Distribution Channel, and Country)